{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:40:28Z","timestamp":1790800828761,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K14974"],"award-info":[{"award-number":["JP18K14974"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Kidney transplant recipients with tacrolimus-based immunosuppressive therapy are often treated with proton-pump inhibitors (PPIs) to prevent gastric ulcer complications. Vonoprazan, a potassium-competitive acid blocker, is a novel PPI possessing different metabolic pathways from conventional PPIs (e.g., omeprazole, lansoprazole and rabeprazole). However, no data are available on the change in blood concentration of tacrolimus after switching rabeprazole, a conventional PPI, to vonoprazan coadministration in the initial period of post-transplantation. This is a retrospective study of 18 kidney transplant recipients. The blood concentration and the concentration to dose (C\/D) ratio of tacrolimus were compared before and after switching from rabeprazole to vonoprazan. Impacts of CYP2C19 and CYP3A5 genetic polymorphisms on the drug\u2013drug interaction were also examined. The median (range) trough concentration of tacrolimus was significantly increased from 5.2 (3.6\u20137.4) to 8.1 (6.1\u201311.7) ng\/mL (p &lt; 0.0005) after switching from rabeprazole to vonoprazan. The C\/D ratio of tacrolimus was also significantly increased from 38.1 (16.5\u2013138.1) to 48.9 (26.2\u2013207.2) (p &lt; 0.0005). The percent changes of tacrolimus concentrations and C\/D were 65.8% and 41.8%, respectively. CYP2C19 and CYP3A5 genetic polymorphisms did not affect the change in concentration and C\/D ratio of tacrolimus. The present study indicates that vonoprazan coadministration increases the tacrolimus concentration regardless of CYP2C19 or CYP3A5 genetic polymorphisms. Thus, frequent monitoring of blood tacrolimus concentration is required when vonoprazan is introduced as an intensive gastric acid blocker in the early phase of post-transplantation.<\/jats:p>","DOI":"10.3390\/jcm10173964","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:59:45Z","timestamp":1630447185000},"page":"3964","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Drug\u2013Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6250-1252","authenticated-orcid":false,"given":"Yoshiharu","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Tsukuba Hospital, Ibaraki 305-8576, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yoshihashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Tsukuba Hospital, Ibaraki 305-8576, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Hepato-Biliary-Pancreatic Surgery, and Organ Transplantation, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinji","family":"Furuya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Hepato-Biliary-Pancreatic Surgery, and Organ Transplantation, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Ohkohchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Hepato-Biliary-Pancreatic Surgery, and Organ Transplantation, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Hepato-Biliary-Pancreatic Surgery, and Organ Transplantation, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4824-3242","authenticated-orcid":false,"given":"Masato","family":"Homma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Tsukuba Hospital, Ibaraki 305-8576, Japan"},{"name":"Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","article-title":"Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference","volume":"31","author":"Wallemacq","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"ref_3","first-page":"1108","article-title":"Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations","volume":"27","author":"Yasuhara","year":"1995","journal-title":"Transpl. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-199610150-00009","article-title":"Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation","volume":"62","author":"Kershner","year":"1996","journal-title":"Transplantation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: A phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.12659\/AOT.909036","article-title":"Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study","volume":"23","author":"Park","year":"2018","journal-title":"Ann. Transpl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/ajt.15081","article-title":"Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial","volume":"19","author":"Ettenger","year":"2019","journal-title":"Am. J. Transpl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ajkd.2017.07.018","article-title":"Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients","volume":"71","author":"Brennan","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_9","first-page":"277","article-title":"Oxidative Metabolism of Tacrolimus and its Metabolite by Human Cytochrome P450 3A Subfamily","volume":"14","author":"Shiraga","year":"1999","journal-title":"Xenobio. Metabol. Dispos."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1248\/yakushi.127.209","article-title":"Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes","volume":"127","author":"Niwa","year":"2007","journal-title":"Yakugaku Zasshi"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1034\/j.1399-0012.2002.01012.x","article-title":"Upper gastrointestinal complications after renal transplantation: A 3-yr sequential study","volume":"16","author":"Logan","year":"2002","journal-title":"Clin. Transpl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00007890-200201270-00028","article-title":"Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: Case of a renal transplant recipient with CYP2C19 gene mutation","volume":"73","author":"Homma","year":"2002","journal-title":"Transplantation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0009-9236(95)90192-2","article-title":"Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4\u2032-hydroxylation status","volume":"58","author":"Yasuda","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2036.1999.00022.x","article-title":"Review article: Cytochrome P450 and the metabolism of proton pump inhibitors\u2014Emphasis on rabeprazole","volume":"13","author":"Ishizaki","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00228-005-0077-8","article-title":"Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes","volume":"62","author":"Miura","year":"2006","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/00498250500111562","article-title":"Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers","volume":"35","author":"Miura","year":"2005","journal-title":"Xenobiotica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1211\/0022357043914","article-title":"Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations","volume":"56","author":"Itagaki","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.110.170274","article-title":"1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases","volume":"335","author":"Hori","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/ctg.2015.18","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese\/non-Japanese Subjects","volume":"6","author":"Sakurai","year":"2015","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study","volume":"65","author":"Murakami","year":"2016","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13876","article-title":"Randomised clinical trial: Efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers\u2014Results from two phase 3, non-inferiority randomised controlled trials","volume":"45","author":"Miwa","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","article-title":"In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker","volume":"47","author":"Yamasaki","year":"2017","journal-title":"Xenobiotica"},{"key":"ref_24","first-page":"14","article-title":"Risk factors for peptic ulcer disease in renal transplant patient\u201311 years of experience from a single center","volume":"62","author":"Chen","year":"2004","journal-title":"Clin. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2133\/dmpk.22.441","article-title":"Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient","volume":"22","author":"Takahashi","year":"2007","journal-title":"Drug Metab. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2133\/dmpk.23.134","article-title":"Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5","volume":"23","author":"Hosohata","year":"2008","journal-title":"Drug Metab. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1248\/bpb.b20-00361","article-title":"Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients","volume":"43","author":"Mei","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40261-016-0488-6","article-title":"Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study","volume":"37","author":"Jenkins","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100407","DOI":"10.1016\/j.dmpk.2021.100407","article-title":"Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms","volume":"40","author":"Watari","year":"2021","journal-title":"Drug Metab. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","article-title":"Human P-glycoprotein transports cyclosporin A and FK506","volume":"268","author":"Saeki","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1248\/bpb.27.1694","article-title":"Effect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cells","volume":"27","author":"Itagaki","year":"2004","journal-title":"Biol. Pharm. Bull."},{"key":"ref_33","unstructured":"The Pharmaceuticals and Medical Devices Agency of Japan (2020, August 01). Drug Approval Review for Vonoprazan Fumarate (in English), Available online: http:\/\/www.pmda.go.jp\/:000211075.pdf."},{"key":"ref_34","unstructured":"Food and Drug Administration (2020, August 01). In Vitro Drug Interaction Studies-Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/134582\/download2020."},{"key":"ref_35","unstructured":"European Medicines Agency (2020, August 01). Guideline on the Investigation of Drug Interactions-Revision 1. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf."},{"key":"ref_36","unstructured":"Pharmaceuticals and Medical Devices Agency (2020, August 01). Guideline on Drug Interaction for Drug Development and Appropriate Provision of Information, Available online: https:\/\/www.pmda.go.jp\/files\/000228122.pdf."},{"key":"ref_37","first-page":"680","article-title":"Diltiazem increases tacrolimus concentrations","volume":"33","author":"Hebert","year":"1999","journal-title":"Ann. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/j.1600-6143.2009.02794.x","article-title":"Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: A randomized, open-label trial","volume":"9","author":"Wlodarczyk","year":"2009","journal-title":"Am. J. Transpl."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/17\/3964\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:58Z","timestamp":1760165638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/17\/3964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":38,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["jcm10173964"],"URL":"https:\/\/doi.org\/10.3390\/jcm10173964","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]}}}